Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Sanofi and Seag e n a nnounce c ollaboration to d evelop and c ommercialize m ultiple n ovel a ntibody- d rug c onjugates

Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates

Seagen released mixed quarterly results and a weak outlook for 2022.

Seagen: Bad Forecast But Good Investment

Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%.

Seagen: Long-Term Pharma Stock To Own Based On Sales Growth And Oncology Portfolio

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Seattle Genetics (SGEN) Up 12.7% Since Last Earnings Report?

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 11:10 a.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen's website at investor.seagen.com. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines

Seagen to Present at the Cowen 42nd Annual Health Care Conference

TOKYO and BOTHELL, Wash., Feb. 28, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Genmab - ADR

Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a

Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

PayPal

These stocks are already down more than 20% this year.

2 Growth Stocks That Have Crashed but Are Still Great Long-Term Buys

Astellas Pharma Inc

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (enfortumab vedotin-ejfv) in muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.  Data will be presented at the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. Data from this late-breaking abstract will be included in an oral presentation (Abstract 435) at th

Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

TOKYO and BOTHELL, Wash., Feb. 14, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

The Nasdaq 100 NDX, -2.08% slumped 1.7% in afternoon trading Thursday, with only 17 of its components gaining ground, after the technology-friendly index ran up 3.3% over the past two days. The index's biggest gainer was Datadog Inc. stock DDOG, +12.28% , which shot up 14.3% over the monitoring and security software platform company reported before the open better-than-expected fourth-quarter results and provided an upbeat first-quarter sales outlook.

Nasdaq 100 suffers broad selloff, led by biotech Seagen and tech heavyweights

Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.

Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down

Investors aren't happy about disappointing forward guidance.

Here's Why Seagen Stock Is Falling Today

Seagen Inc  SGEN reported Q4 revenues of $429.9 million, compared to $601.3 million a year ago, beating the consensus of $407.21 million. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are Seagen Shares Sinking Today?

Seagen Inc. (SGEN) CEO Clay Siegall on Q4 2021 Results - Earnings Call Transcript

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2021. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its robust oncology pipeline. “Total revenues of $1.6 billion in 2021 were driven by strong net product sales and reflect gro

Seagen Reports Fourth Quarter and Full Year 2021 Financial Results

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen's website at investor.seagen.com. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative

Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)-- #Hodgkinlymphoma--ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma

ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Seattle Genetics (SGEN) Q4 Earnings Expected to Decline

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen appoints Heeson EVP

Seagen Appoints Lee Heeson as Executive Vice President, Commercial International

Netflix

Tesla

Align Technology

Microchip Technology

Tech stocks got off to a mixed start Monday morning. The Nasdaq was up more than 1%, while the Dow Jones industrials were down 0.3% and the S&P 500 was 0.1% higher.

Monday Morning's 5 Tech Stock Movers Include Netflix and Tesla

BioLife Solutions

Incyte

Try your hand at morphing science and business for a great investment opportunity in biotech.

Best Biotech Stocks to Invest in Now

Seagen Inc (NASDAQ: SGEN) announced data from a Phase 1 trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The data were shared at the ASCO GI annual meeting.

News for Seagen Stock (SGEN)